NCT07459543 2026-03-09A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In IndiaBristol-Myers SquibbPhase 4 Not yet recruiting30 enrolled
NCT06362369 2025-09-17A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy7 Hills Pharma, LLCPhase 1/2 Recruiting126 enrolled
NCT05704985 2025-05-29Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsDEKA BiosciencesPhase 1 Active not recruiting39 enrolled
NCT02897765 2021-02-25A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerBioNTech SEPhase 1 Completed34 enrolled
NCT02302339 2019-09-06A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaCelldex TherapeuticsPhase 2 Terminated132 enrolled 16 charts